Endocrine Abstracts

Thyroid carcinoma is collectively the most common of the endocrine cancers and overall has a good prognosis if diagnosed early. However, the molecular events underlying development of the two most common types, follicular (FTC) and papillary thyroid carcinoma (PTC), is not well understood. Furthermore, pre-operative distinction between FTC and benign follicular adenomas (FA) by fine-needle aspiration remains a challenge. Microarray expression analysis is a powerful tool that m...

Introduction: There are limited data on the effectiveness and safety of GHRT in older patients with AGHD. We compared real-world GHRT outcomes in older (aged ≥60 years) vs middle-aged (35–<60 years) adults.Methods: NordiNet® IOS (NCT00960128) and ANSWER (NCT01009905) were non-interventional studies investigating long-term effectiveness and safety of GHRT with Norditropin® (somatropin, Novo Nordisk). Safety was assessed in the ful...

Background/Aim: Classic 21-hydroxylase deficiency (21HD) presents some traits of the metabolic syndrome.Aim: To investigate early metabolic alterations in lipid and adipokine profile together with markers of subclinical inflammation in children and young adults with classic 21HD, which could predict early atherogenesis.Patients und Methods: Thirty nine patients with classic 21HD (4–30 years); 39 age-, sex- and BMI-matched heal...

Hypophosphatasia (HPP), a heritable metabolic bone disease, results from low alkaline phosphatase (TNSALP) activity. Inorganic pyrophosphate (PPi), an inhibitor of mineralization, and pyridoxal 5′-phosphate (PLP), are substrates that accumulate in HPP. There is no approved therapy. ENB-0040, a bone-targeted, recombinant, human TNSALP improves skeletal mineralization in affected infants and children with HPP.Objective: Evaluate substrate levels and ...